Lantern Pharma announced that the FDA has granted fast track designation for investigational drug candidate, LP-184, for treatment of Glioblastoma.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter